Showing 1 - 10 of 24
Persistent link: https://www.econbiz.de/10000781646
Persistent link: https://www.econbiz.de/10000805541
Persistent link: https://www.econbiz.de/10001112322
The competitiveness of countries and that of firms are different concepts. EU GDP is stable at two-thirds of the US, but productivity growth has lagged since the 1990s. The EU does better on wealth equality and clean-tech export shares. The EU faces two supply-side disadvantages: high energy...
Persistent link: https://www.econbiz.de/10014537188
This paper reviews the state of EU competitiveness and introduces a strategy to improve it, based on medium-term, sector-level coordination of Member State reform policies and/or investments. The idea is illustrated with two examples: an investment and reform programme to create a single EU...
Persistent link: https://www.econbiz.de/10015277261
In its May 2005 the Group of Economic Policy Analysis (GEPA) discussed the issue of EU competitiveness and industrial location. At that meeting, a request was made for BEPA to prepare a report (i) taking stock of the phenomena of delocalisation and outsourcing in particular and globalisation in...
Persistent link: https://www.econbiz.de/10015316186
We investigate patterns in common ownership networks between firms that are active in the U.S. pharmaceutical industry for the period 2004–2014. Our main findings are that “brand firms”—that is, firms that have research and development capabilities and launch new drugs—exhibit...
Persistent link: https://www.econbiz.de/10013460020
Ownership of publicly listed German companies has undergone significant changes in recent years. The aim of this report is to document these trends since 2007 and analyze the extent to which firms that compete in the same product market are owned by the same investors, which is known as common...
Persistent link: https://www.econbiz.de/10011689848
Persistent link: https://www.econbiz.de/10012316998
We investigate patterns in common ownership networks between firms that are active in the US pharmaceutical industry for the period 2004-2014. Our main findings are that "brand firms" - i.e. firms that have R&D capabilities and launch new drugs - exhibit relatively dense common ownership...
Persistent link: https://www.econbiz.de/10012384544